Curis to Present at Techvest European Healthcare Conference
Wednesday May 14, 11:13 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 14, 2003--Curis, Inc. (NASDAQ:CRIS - News) announced today that Dr. Christopher U. Missling, CURIS' Chief Financial Officer, will speak at the upcoming Techvest annual European healthcare conference entitled "Opportunities in Global Biotech".
The conference will be held in Amsterdam, The Netherlands, on May 19-20.
The Techvest conference in Europe is held annually to promote continued contact between biotechnology companies and venture capitalists and institutional investors and to provide a platform to introduce new biotechnology companies to the investment community. Dr. Missling will provide an update on Curis' therapeutic product development programs and its plans for partnering with pharmaceutical companies.
About Curis, Inc.
Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of kidney disease, neurological disorders, cancer, and alopecia (hair loss). For more information, please visit the Curis web site at www.Curis.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. Such statements may contain the words "believes", "expects", "anticipates", "plans", "estimates" or similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements. Actual results can be affected by, among other things, uncertainties relating to product development, clinical trials, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, changes in or an inability to execute Curis' realigned business strategy and other risk factors identified in Curis' most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release.
--------------------------------------------------------------------------------
Contact:
Curis, Inc.
Christopher U. Missling, Ph.D., 617/503-6587
Marc F. Charette, Ph.D., 617/503-6629
--------------------------------------------------------------------------------
Source: Curis, Inc. |
